Patents by Inventor Robert Volkmann

Robert Volkmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180244690
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Patent number: 10052306
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 21, 2018
    Assignee: CADENT THERAPEUTICS, INC.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Patent number: 10017529
    Abstract: The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: July 10, 2018
    Assignee: BioPharma Works LLC
    Inventors: Anton F Fliri, Robert A Volkmann
  • Patent number: 9988394
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 5, 2018
    Assignee: Lixte Biotechnology Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Patent number: 9963434
    Abstract: Compounds of the Formula wherein A, B, C, D, X, Y, Z, R1, R2, R2?, R3 and n are described herein, selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: May 8, 2018
    Assignee: Luc Therapeutics, Inc.
    Inventors: David R Anderson, Robert A Volkmann
  • Publication number: 20180111902
    Abstract: The present invention relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I where R1, R2, L1, L2, X, Y, and Y? are described therein. In an aspect, compounds of formula I are described and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or stereoisomers thereof wherein: L1 is straight or branched C1-C5 alkyl optionally substituted with one or more substituents selected from the group consisting of OH, ORIO, NH2, NHRio, and N(Rlo)(Rio?) provided that no more than one oxygen or nitrogen is attached to any carbon.
    Type: Application
    Filed: September 23, 2015
    Publication date: April 26, 2018
    Applicant: Luc Therapeutics, Inc.
    Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITI
  • Publication number: 20170247400
    Abstract: The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.
    Type: Application
    Filed: September 16, 2015
    Publication date: August 31, 2017
    Inventors: Anton F. Fliri, Robert A. Volkmann
  • Publication number: 20170071906
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Publication number: 20170022245
    Abstract: The present invention is directed to Ganaxolone prodrugs with increased aqueous solubility and oral bioavailability relative to Ganaxolone and that enable development of stable extended release formulations which offer a significant therapeutic advantage and improved patience compliance by enabling treatments with lower doses over prolonged periods of time.
    Type: Application
    Filed: November 26, 2014
    Publication date: January 26, 2017
    Applicant: BioPharma Works
    Inventors: Robert A Volkmann, Anthony Marfat
  • Patent number: 9540324
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: January 10, 2017
    Assignee: LUC THERAPEUTICS, INC.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Publication number: 20160333024
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 13, 2016
    Publication date: November 17, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: JOHN S. KOVACH, ROBERT VOLKMANN, ANTHONY MARFAT
  • Patent number: 9487531
    Abstract: The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: November 8, 2016
    Assignee: BioPharma Works LLC
    Inventors: Robert Volkmann, Anthony Marfat, Peter Cornelius, Panayiotis Zagouras, Frederick Raymond Nelson, Anton Franz Joseph Fliri
  • Publication number: 20160311782
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Application
    Filed: September 26, 2014
    Publication date: October 27, 2016
    Inventors: David R Anderson, Robert A Volkmann
  • Publication number: 20160259847
    Abstract: The disclosed embodiments relate to data mining methods for determining economically valuable cause effect relationships between objects and properties associated with objects using co-occurrence frequency measurements of semantic terms characterizing observations of properties, effects or behaviors of objects in different environments and using these measurements as object descriptors in calculations determining object similarities.
    Type: Application
    Filed: August 8, 2014
    Publication date: September 8, 2016
    Inventors: Anton F. FLIRI, William T. LOGING, Robert A. VOLKMANN
  • Publication number: 20160083393
    Abstract: The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations containing said. compounds or pharmaceutically acceptable salts thereof, which are capable of providing controlled release of the opioid drug upon administration to a patient in order to treat pain.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 24, 2016
    Inventor: Robert VOLKMANN
  • Publication number: 20160068537
    Abstract: The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 10, 2016
    Inventors: Robert Volkmann, Anthony Marfat, Peter Cornelius, Panayiotis Zagouras, Frederick Raymond Nelson, Anton Franz Joseph Fliri
  • Publication number: 20150225342
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 13, 2015
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Publication number: 20150141433
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 21, 2015
    Inventors: David R. Anderson, Robert A. Volkmann
  • Publication number: 20140323416
    Abstract: The aspects of the present disclosure are directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. In particular, to 5-methyldihydromorphone prodrug compounds described in general Formula I and II and the use of the compounds for treating pain associated with a variety of chronic human disorders including for example neuropathic pain and pain associated with cancer, surgeries or injuries.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 30, 2014
    Inventors: Anthony MARFAT, Peter CORNELIUS, Robert VOLKMANN, Panayiotis ZAGOURAS, Frederick Raymond NELSON, Anton Franz Joseph FLIRI
  • Publication number: 20060058267
    Abstract: This invention relates to methods of treating neurodegenerative diseases and inhibiting neurological damage, comprising administering to a patient in need of such treatment an N-NOS inhibitor in combination with a GABA-A receptor modulator.
    Type: Application
    Filed: October 25, 2005
    Publication date: March 16, 2006
    Inventors: John Lowe, Robert Volkmann